Perceptive Advisors LLC
Perceptive Advisors LLC reported 101 US-listed holdings worth $6.43 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Praxis Precision Medicines I (10.6%), Spyre Therapeutics Inc. (6.0%) and Celcuity Inc. (5.2%). Against the quarter before, it opened 23 positions, added to 29, trimmed 26 and sold out of 13.
Reported holdings$6.43B+27.3% on Q1 2026
Positions101+10 on Q1 2026
The largest ten49.0%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedAdded toHeldTrimmed
The 14 largest of its 101 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 23Added 29Held 23Trimmed 26Sold out 13
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 23
- Ascendis Pharma A/s ASND$310.4 million
- Kardigan Inc. KARD$195.6 million
- Avalyn Pharma Inc. AVLN$88.1 million
- Biogen Inc. BIIB$59.7 million
- UnitedHealth Group Inc. UNH$48.5 million
- Charles River Laboratories International, Inc. CRL$31.8 million
- Danaher Corp. DHR$24.8 million
- Adlai Nortye Ltd ANL$20.6 million
and 15 more in the table below
Added to 29
- Relay Therapeutics Inc. RLAY+4.4 million shares · +45%
- Tango Therapeutics Inc. TNGX+2.6 million shares · +318%
- Revolution Medicines, Inc. RVMD+269,000 shares · +104%
- Spyre Therapeutics Inc. SYRE+536,271 shares · +14%
- Corcept Therapeutics Inc. CORT+348,385 shares · +697%
- Biocryst Pharmaceuticals Inc. BCRX+2.9 million shares · +39%
- Rhythm Pharmaceuticals Inc. RYTM+212,500 shares · +9%
- Adaptive Biotechnologies Corporation ADPT+1.1 million shares · +698%
and 21 more in the table below
Trimmed 26
- Dyne Therapeutics Inc. DYN-2.0 million shares · -42%
- Guardant Health Inc. GH-258,673 shares · -86%
- Abivax SA ABVX-254,884 shares · -77%
- Apogee Therapeutics Inc. APGE-232,271 shares · -15%
- Protagonist Therapeutics, Inc. PTGX-249,000 shares · -20%
- Travere Therapeutics Inc. TVTX-389,977 shares · -9%
- Axogen Inc. AXGN-450,000 shares · -65%
- Inhibrx Biosciences Inc. INBX-144,944 shares · -10%
and 18 more in the table below
Sold out of 13
- Ascendis Pharma A/s ASND$350.3 million last quarter
- Centessa Pharmaceuticals PLC CNTA$208.9 million last quarter
- Engene Holdings Inc. ENGN$39.7 million last quarter
- Day One Biopharmaceuticals I DAWN$37.6 million last quarter
- Bright Minds Biosciences Inc. DRUG$27.5 million last quarter
- Belite Bio Inc. BLTE$24.2 million last quarter
- Evommune Inc. EVMN$10.3 million last quarter
- Neumora Therapeutics Inc. NMRA$10.0 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Praxis Precision Medicines I PRAX | 2,035,986 | $681.6 million | 10.61% | no change |
| Spyre Therapeutics Inc. SYRE | 4,319,496 | $383.5 million | 5.97% | +536,271 |
| Celcuity Inc. CELC | 3,197,200 | $334.5 million | 5.21% | +70,000 |
| Ascendis Pharma A/s ASND | 1,163,721 | $310.4 million | 4.83% | new |
| Rhythm Pharmaceuticals Inc. RYTM | 2,586,295 | $287.2 million | 4.47% | +212,500 |
| Roivant Sciences Ltd. ROIV | 8,085,461 | $286.1 million | 4.45% | -200,000 |
| Relay Therapeutics Inc. RLAY | 14,106,187 | $263.9 million | 4.11% | +4,355,046 |
| Travere Therapeutics Inc. TVTX | 3,752,574 | $213.2 million | 3.32% | -389,977 |
| Kardigan Inc. KARD | 8,200,662 | $195.6 million | 3.04% | new |
| Nuvalent Inc. NUVL | 1,580,505 | $195.2 million | 3.04% | no change |
| Edgewise Therapeutics Inc. EWTX | 4,373,974 | $177.7 million | 2.77% | -50,000 |
| Apogee Therapeutics Inc. APGE | 1,308,113 | $173.6 million | 2.70% | -232,271 |
| Amylyx Pharmaceuticals Inc. AMLX | 8,334,882 | $149.7 million | 2.33% | +50,000 |
| Meiragtx Holdings PLC MGTX | 10,786,658 | $145.7 million | 2.27% | +460,555 |
| Oruka Therapeutics Inc. ORKA | 1,345,063 | $128.0 million | 1.99% | -50,438 |
| Inhibrx Biosciences Inc. INBX | 1,297,763 | $123.0 million | 1.91% | -144,944 |
| Protagonist Therapeutics, Inc. PTGX | 981,879 | $120.4 million | 1.87% | -249,000 |
| Solid Biosciences Inc. SLDB | 11,906,646 | $118.9 million | 1.85% | no change |
| Zymeworks Inc. ZYME | 4,182,953 | $109.3 million | 1.70% | +672,875 |
| Tango Therapeutics Inc. TNGX | 3,377,000 | $105.6 million | 1.64% | +2,568,847 |
| Immatics N.V IMTX | 10,383,456 | $105.2 million | 1.64% | no change |
| Nurix Therapeutics Inc. NRIX | 4,320,422 | $104.8 million | 1.63% | +609,545 |
| Biocryst Pharmaceuticals Inc. BCRX | 10,308,888 | $103.1 million | 1.60% | +2,874,855 |
| Revolution Medicines, Inc. RVMD | 527,600 | $98.8 million | 1.54% | +269,000 |
| Avalyn Pharma Inc. AVLN | 2,675,296 | $88.1 million | 1.37% | new |
| Dyne Therapeutics Inc. DYN | 2,689,235 | $59.7 million | 0.93% | -1,979,604 |
| Biogen Inc. BIIB | 276,173 | $59.7 million | 0.93% | new |
| Immunovant Inc. IMVT | 1,357,383 | $52.3 million | 0.81% | -240,000 |
| UnitedHealth Group Inc. UNH | 116,806 | $48.5 million | 0.76% | new |
| Ionis Pharmaceuticals Inc. IONS | 566,000 | $44.9 million | 0.70% | +62,000 |
| Sutro Biopharma Inc. STRO | 1,304,846 | $43.3 million | 0.67% | +589,539 |
| Alto Neuroscience Inc. ANRO | 1,609,893 | $42.5 million | 0.66% | -400,000 |
| Jazz Pharmaceuticals plc JAZZ | 170,000 | $41.0 million | 0.64% | no change |
| Corvus Pharmaceuticals Inc. CRVS | 2,667,441 | $39.9 million | 0.62% | +375,000 |
| Sionna Therapeutics Inc SION | 905,000 | $39.8 million | 0.62% | +246,561 |
| Cytomx Therapeutics Inc. CTMX | 10,439,185 | $39.1 million | 0.61% | +340,361 |
| Artivion, Inc. AORT | 1,737,290 | $39.0 million | 0.61% | +100,000 |
| X4 Pharmaceuticals Inc. XFOR | 7,933,491 | $37.0 million | 0.58% | +1,195,843 |
| Corcept Therapeutics Inc. CORT | 398,385 | $34.6 million | 0.54% | +348,385 |
| Repligen Corp. RGEN | 248,212 | $33.9 million | 0.53% | -32,329 |
| Anteris Technologies Global AVR | 3,425,476 | $33.7 million | 0.53% | no change |
| Rapport Therapeutics Inc. RAPP | 773,342 | $32.2 million | 0.50% | +99,419 |
| Galecto Inc. DMRA | 1,223,000 | $31.8 million | 0.50% | no change |
| Charles River Laboratories International, Inc. CRL | 140,000 | $31.8 million | 0.49% | new |
| Axsome Therapeutics Inc. AXSM | 118,450 | $29.0 million | 0.45% | -31,500 |
| DBV Technologies S A DBVT | 1,653,350 | $27.1 million | 0.42% | +688,959 |
| Irhythm Technologies Inc. IRTC | 223,766 | $26.6 million | 0.41% | +118,740 |
| Adaptive Biotechnologies Corporation ADPT | 1,217,325 | $26.1 million | 0.41% | +1,064,825 |
| Sab Biotherapeutics Inc. SABS | 6,627,501 | $25.8 million | 0.40% | +195,758 |
| Danaher Corp. DHR | 130,000 | $24.8 million | 0.39% | new |
| Tenax Therapeutics Inc. TENX | 1,700,000 | $24.7 million | 0.38% | +252,218 |
| Nautilus Biotechnology Inc. NAUT | 11,634,211 | $21.8 million | 0.34% | -960,000 |
| Orchestra Biomed Holdings in OBIO | 5,037,906 | $21.7 million | 0.34% | no change |
| Intuitive Surgical Inc. ISRG | 51,884 | $20.6 million | 0.32% | -33,535 |
| Adlai Nortye Ltd ANL | 1,793,190 | $20.6 million | 0.32% | new |
| Contineum Therapeutics Inc. CTNM | 1,255,592 | $20.6 million | 0.32% | no change |
| Nuvectis Pharma Inc. NVCT | 1,000,000 | $18.4 million | 0.29% | new |
| Palisade Bio Inc. PALI | 8,425,065 | $17.6 million | 0.27% | -503,084 |
| Omada Health Inc. OMDA | 786,330 | $17.3 million | 0.27% | no change |
| Athira Pharma Inc. LONA | 1,859,322 | $17.1 million | 0.27% | no change |
| Evolus Inc. EOLS | 2,459,285 | $17.1 million | 0.27% | +1,172,423 |
| Invivyd Inc. IVVD | 18,490,636 | $16.1 million | 0.25% | -2,368,667 |
| Mirum Pharmaceuticals Inc. MIRM | 115,391 | $13.5 million | 0.21% | new |
| Surrozen Inc. SRZN | 503,985 | $13.1 million | 0.20% | +274,592 |
| Beta Bionics Inc BBNX | 832,944 | $13.1 million | 0.20% | -10,000 |
| Axogen Inc. AXGN | 247,312 | $11.4 million | 0.18% | -450,000 |
| Oscar Health Inc. Class A OSCR | 400,000 | $11.4 million | 0.18% | new |
| Oculis Holding AG OCS | 808,827 | $11.2 million | 0.17% | +315,000 |
| Seaport Therapeutics Inc. SPTX | 500,000 | $10.9 million | 0.17% | new |
| Viridian Therapeutics Inc. VRDN | 581,980 | $10.7 million | 0.17% | -588,849 |
| Boston Scientific Corp. BSX | 250,000 | $10.7 million | 0.17% | new |
| Billiontoone Inc. BLLN | 86,812 | $10.4 million | 0.16% | -5,000 |
| Abivax SA ABVX | 74,000 | $9.9 million | 0.15% | -254,884 |
| Natera Inc Com NTRA | 34,689 | $9.4 million | 0.15% | new |
| Engene Therapeut ENGN | 4,822,169 | $8.3 million | 0.13% | new |
| Research Alliance Corp Iii Ord Shs Cl A RACC | 750,000 | $8.0 million | 0.12% | new |
| Agomab Therapeutics NV AGMB | 600,000 | $7.8 million | 0.12% | no change |
| Cullinan Therapeutics Inc. CGEM | 426,478 | $7.8 million | 0.12% | new |
| Uniqure NV QURE | 168,000 | $7.7 million | 0.12% | new |
| Mobia Med Inc. MOBI | 523,654 | $7.0 million | 0.11% | new |
| Adagio Med Hldgs Inc. ADGM | 9,876,586 | $6.4 million | 0.10% | +10 |
| Guardant Health Inc. GH | 41,327 | $6.2 million | 0.10% | -258,673 |
| Phathom Pharmaceuticals Inc. PHAT | 532,000 | $5.8 million | 0.09% | -393,000 |
| Outlook Therapeutics Inc. Com OTLK | 3,139,216 | $5.0 million | 0.08% | new |
| Cogent Biosciences Inc. COGT | 121,082 | $4.7 million | 0.07% | no change |
| Edesa Biotech Inc. EDSA | 563,239 | $4.6 million | 0.07% | no change |
| Avalo Therapeutics Inc. AVTX | 219,813 | $4.1 million | 0.06% | +80,146 |
| Twist Bioscience Corp. TWST | 36,812 | $3.8 million | 0.06% | -113,188 |
| Crescent Biopharma Inc. CBIO | 206,942 | $3.7 million | 0.06% | no change |
| Xeris Biopharma Holdings Inc. XERS | 467,013 | $3.7 million | 0.06% | new |
| Outset Med Inc. OM | 833,333 | $3.6 million | 0.06% | no change |
| Biodesix Inc. BDSX | 108,694 | $2.5 million | 0.04% | new |
| Revolution Medicines Inc. RVMDW | 250,000 | $2.3 million | 0.04% | no change |
| Connect Biopharma Hldgs Ltd CNTB | 792,696 | $1.9 million | 0.03% | no change |
| Kiora Pharmaceuticals Inc. KPRX | 438,471 | $1.2 million | 0.02% | new |
| Medline Inc. MDLN | 28,000 | $1.1 million | 0.02% | no change |
| Adma Biologics, Inc. ADMA | 113,765 | $952,213 | 0.01% | -353,468 |
| Cumberland Pharmaceuticals I CPIX | 96,982 | $628,443 | 0.01% | -99,996 |
| Exagen Inc. XGN | 114,893 | $534,252 | 0.01% | no change |
| Ensysce Biosciences Inc. ENSC | 86,666 | $25,133 | 0.00% | no change |
| Surrozen Inc SRZNW | 166,666 | $2,750 | 0.00% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read more
Change is shares against its 13F for the quarter before; the 13 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| Moderna, Inc. MRNA | Puts | 1,000,000 | $70.0 million |
| SPDR Ser Trust XBI | Puts | 300,000 | $47.5 million |
| Eyepoint Pharmaceuticals Inc. EYPT | Puts | 2,000,000 | $28.6 million |
| Capricor Therapeutics Inc. CAPR | Calls | 1,000,000 | $24.1 million |
| Sellas Life Sciences Group I SLS | Puts | 1,500,000 | $22.1 million |
| Newamsterdam Pharma Company NAMS | Puts | 500,000 | $16.9 million |
| Capricor Therapeutics Inc. CAPR | Puts | 500,000 | $12.0 million |
7 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.